It is noteworthy that response rates to neoadjuvant treatment are variable according to tumor phenotype, with complete pathological response rates ranging from 7–16% for tumors with positive hormone receptors (higher for high-grade tumors), 34% for triple-negative tumors, 30% for luminal tumors B-HER-2-positive (hormone receptor and HER-2 gene product expression-positive), and about 50% when tumors present expression of the HER-2 gene product and negative hormone receptors. This evidence concerns the gene ERBB2 and neoplasm.